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Abstract
Objective: The aim of this study is to describe the evolution of multimorbidity.
Study Design and Setting: Data from 1854 South Australians who participated in the North West Adelaide longitudinal
Health Study(NWAHS) was collected between baseline (2000–2002) and follow-up (2008–2010). Status for eight chronic
diseases (CDs) was determined by biomedical measurement or self-report. Chronic disease (CD) mean age of occurrence
and order of appearance was investigated.
Results: The prevalence of multimorbidity increased from 32% to 64% during the 7.861.1 years of follow-up. The estimated
mean age of onset of a new CD was significantly older for hypertension, cardiovascular disease (CVD) and chronic
obstructive pulmonary disease (COPD) and younger for hypercholesterolemia, asthma and other mental problem.
Hypercholesterolemia was more likely to develop as a first than as a subsequent CD (39%vs.16%, p,0.0001) while CVD
(1%vs.5%, p,0.0001), diabetes (5%vs.11%, p,0.001) and COPD (6%vs.16%, p,0.0001) were less likely. The presence of
mood disorders at baseline was associated with an increased risk of developing other mental disorders (36%vs.12%, p,
0.0001), diabetes (18%vs.9%, p,0.01) and asthma (30%vs.21%, p,0.05).
Conclusion: Longitudinal data could be used to study the evolution of multimorbidity and could provide information on
CDs mean age of occurrence, order of appearance and impact on the development of future CDs.
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Introduction
Today, chronic diseases (CDs) are highly prevalent and
constitute the leading cause of death in the world [1]. However,
advances in the management of CDs has slowed the progression of
diseases and delayed related death in developed countries. Such
changes have led to an increase in multimorbidity [2,3,4,5],
mainly defined as the presence of two or more medical conditions
in an individual [6]. In general, multimorbidity includes only
CDand its prevalence increases with age [3,7] and social
deprivation [7,8]. It has been shown to be associated with
increased medical consultation, prescription, psychological dis-
tress, emergency utilization, hospital length of stay, and mortality
rates [9,10,11,12].
Multimorbidity is part of a continuum ranging from healthy
status, development of a single CDand then progression to
multimorbidity with the addition of a further CD. The term
‘evolution of multimorbidity’ could be used to describe this whole
process. The knowledge retrieved from a study of evolution of
multimorbidity has the potential to identify populations at high
risk of developing multimorbidity as well as repartitioning CDs
across this continuum. Few studies [13,14,15,16] have examined
multimorbidity from a longitudinal perspective. Those studies
focused mostly on the impact of CDs on disability, functional
decline and mortality [14] or its relationship with nutrition [16]. In
addition to the strength of association between CDs at a specific
time point (e.g. observed over expected ratio) [17], a longitudinal
follow-up design is rarely used in the context of multimorbidity
and could help understand causality [15]. To the best of our
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knowledge, no study has used a longitudinal study design to
investigate the evolution of multimorbidity. This study aims to
characterize evolution of multimorbidity by 1) characterizing the
magnitude of the evolution of the prevalence of multimorbidity
through time, 2) determining the order in which CDs appear and
3) identifying CDs present at baseline which are associated with an
increased risk of developing other CDs.
Methods
Study design
The North West Adelaide Health Longitudinal Study
(NWAHS) is a representative population sample of people aged
18 years or older living in the north western suburbs of Adelaide,
South Australia (regional population 0.6 million) and covers a
broad range of socioeconomic areas. The study’s purpose is to
investigate the prevalence of chronic conditions and associated
health-related risk factors, and to monitor progression of diseases
over time in order to help plan health care provision. The sample
is representative of the community profile of Adelaide [18,19,20]
and has been described previously in detail [18,19]. Briefly,
between 2000 and 2002, 4060 adults completed a telephone
interview, self-completed questionnaire and clinic biomedical
assessment (including blood sample). This represents 50% of the
people invited to take part in the study. Persons aged $18 years
from households selected at random from the electronic white
pages directory were eligible. Respondents completed a self-report
questionnaire related to health status and additional demographic
details and underwent clinical assessment, including measurement
of blood pressure, height, weight, fasting glucose and lipid levels.
Stage 2 (2004 to 2006) and Stage 3 (2008 to 2010) included a
Computer Assisted Telephone Interview (CATI), a self completed
questionnaire and a biomedical examination at a clinic. For Stage
2, 3564 of the participants were interviewed and/or completed a
questionnaire and 81.0% of the eligible sample (n = 3205) attended
a clinic appointment. For Stage 3, 2871 of the participants were
interviewed and/or completed a questionnaire and 2487 individ-
uals attended clinics. Overall, complete clinical and self reports
information at each phase and for every CD was available for
1854 individuals (46% of the baseline sample). In order to
maximize follow-up duration, the data from stage 1 and 3 were
used, but data from stage 2 also contributed to establishing CD
status at stage 3. Stage 1 and 3 are considered as baseline and
follow-up throughout this article. A recently published paper by
our group directly addresses the representativeness of the stage 3
cohort [21]. Briefly, it was found that compared to the census, and
a sample of the population surveyed by CATI over the same
period, those in the stage 3 of NWAHS were older, more likely to
have a trade or certificate, to be employed, to be a non-smoker
and to have a higher income. No significant differences were found
in gender proportion and alcohol consumption. Requests for de-
identified data can be sent to the Chief investigator (anne.taylor@
adelaide.edu.au) or the study co-ordinator (Janet.grant@adelaide.
edu.au). The study was approved by institutional ethics commit-
tees of the North West Adelaide Health Service, and all subjects
gave written informed consent.
Physical and Socio-demographic characteristics
Height was measured to the nearest 0.5 centimetres using a
stadiometer, and weight to the nearest 0.1 kilogram in light
clothing and without shoes using standard digital scales. Body
mass index (BMI) was calculated as weight (kg)/height (m)2.
Information on socio-demographic and other lifestyle factors were
also collected (Table 1).
Chronic disease status assessments
CD status was determined for the following eight conditions:
asthma, cardiovascular disease and stroke (CVD), chronic
obstructive pulmonary disease (COPD), diabetes, mood and
anxiety disorders, any other mental disorders, hypercholesterol-
emia and hypertension. Asthma, COPD, diabetes, hypercholes-
terolemia and hypertension were determined at the clinic visit. A
fasting blood test was performed to determine total cholesterol and
glucose levels (FPG). A person was deemed to have diabetes if they
self-reported having ever been told by a doctor they had the
condition, self-reported utilisation of glucose lowering drugs or by
measurement at the clinic (FPG$7.0 mmol/L) [22,23]. High
cholesterol was defined as total blood cholesterol $5.5 mmol/L or
self report of cholesterol lowering drugs [24]. Two blood pressure
measurements were taken five to ten minutes apart using a
standard, calibrated blood pressure sphygmomanometer, while the
participant was relaxed and seated. The average of these two
recorded measures was used in the analyses. High blood pressure
was defined as systolic blood pressure $140 mm Hg and/or
diastolic blood pressure $90 mm Hg or the self-reported use of
drugs to lower blood pressure. Participants were tested for asthma
and COPD at the clinic visit by spirometry before and after the use
of a beta agonist. A positive COPD case was present if FEV1/
FVC,70% and for asthma if FEV1$12% and .200 ml or
absolute change greater or equal to 400 ml from pre salbutamol to
post salbutamol [25,26]. Status for asthma was determined using
clinical and self-report while COPD was mainly based on clinical
measurement as previously described [25,26]. Participants self-
reported if they had ever been told by a doctor they had CVD
(heart attack, stroke, angina) or a mental health condition (anxiety,
depression or other mental health problem). Mental health
condition was then split between mood and anxiety disorders
and other mental disorders. An individual having a diagnosis for a
CD was considered as having it for every phase afterwards.
Statistical analyses
Mean incident age of onset of a CD developed during the
follow-up period was calculated based on age at the time of follow-
up. Mean incident age of onset of a CD was compared with those
that developed another CD by using independent sample student t
test. For the population that developed a CD, multinomial logistic
regression (MLR) was used to determine significant differences in
the count and individual proportion of CDs developed between
those who were healthy or had at least one CD at baseline. Among
those with a CD at baseline, MLR was also used to determine
significant differences in the count and proportions of those with
CDs between who developed CDs or not. Difference in CDs
developed by the subgroups with asthma or mood and anxiety
disorders at baseline was determined using MLR. The control
group consisted of those who developed another CD. All MLR
analyses were undertaken for crude; adjusted by age and sex; and
adjusted for age, sex, BMI status, marital status, working status,
annual income and education. For all the MLR analyses,
unadjusted odds ratios were also determined. Unless stated
otherwise, (95%) confidence intervals are presented in the figures
and standard deviation in the text while the p value found in the
text is adjusted for both age and sex. All analyses were carried out
using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA) and a p,
0.05 was considered significant.
Evolution of Multimorbidity
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Table 1. Physical and socio-demographic characteristics of the 1854 participants to the North West Adelaide Health Study at
baseline (2002).
Variable N (%)













Bachelor degree or higher 241 (13)
Do not know/refused 41 (2)
Occupation
Full time employed 782 (42)
Part time/casual employment 341 (18)
Unemployed 50 (3)
Home duties 235 (13)
Retired 364 (20)
Student 30 (2)
Other/not stated 52 (3)
Annual Income
Up to $ 12,000 192 (10)
$ 12,001–$ 20,000 235 (13)
$ 20,001–$ 40,000 485 (26)
$ 40,001–$ 60,000 419 (23)
$ 60,001–$ 80,000 223 (12)
Over $ 80,000 228 (12)
Do not know/refused 72 (4)
Do you receive pension or benefits from social security?
Yes 584 (32)
No 1251 (68)
Do not know/not stated 19 (1)
Marital status
Married/living with partner 1237 (67)
Separated/divorced 272 (15)
Widowed 130 (7)
Never married 207 (11)
Not stated 8 (0)
Family structure (from phase 2)
A family with a child 562 (30)
A step or blended family 82 (4)
A sole parent family 82 (4)
Shared care parenting 33 (2)
Adult living alone 341 (18)
Adult living with partner and with no child 582 (31)
Evolution of Multimorbidity
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Results
Description of the cohort
Baseline physical and socio-demographic characteristics of the
cohort are described in Table 1. Briefly, the cohort (mean age 6
standard deviation at baseline: 50614 years old) included slightly
more females (52%), people working (60%) and married (67%).
The mean follow-up period of the 1854 individuals included in the
cohort was 7.861.1 years.
Chronic diseases and multimorbidity status
CD status throughout the study is presented in Table 2. At
baseline, among the 1854 participants, 1299 (70%) had at least
one CD at baseline. The prevalence of multimorbidity doubled
from baseline (32%; 95%CI: 30–34%) to follow-up (64%; 62–
66%). Accordingly, the mean number of CDs per person increased
from 1.1260.99 to 2.0961.30. At baseline, hypercholesterolemia
and hypertension were the most common CDs with prevalences of
41% (39–43%) and 28% (26–30%) respectively. At follow-up,
these prevalences increased to 64% (62–66%) and 48% (46–50%)
respectively. During the study, a total of 1152 participants (62%;
60–64%) developed at least one CD while 473 (25%; 23–27%)
developed at least two CDs. Among individuals without a CD at
baseline, 30% (28–32%) stayed healthy (9% of the total cohort)
while 70% (68–72%) developed at least one CD (21% of the
cohort). Among the 1299 participants with at least one CD at
baseline, 58% (56–60%) developed at least another one (41% of
the cohort) while 42% (40–44%) did not (29% of the cohort).
Mean age of occurrence of individual chronic diseases
developed during the follow-up
Individuals who did not develop a CD (n= 702) were
significantly younger than those that developed two (n= 339) or
three CDs (n= 134) during the follow-up period (mean 6 S.E., 2
461, p,0.0001 and 2561, p,0.01 years old respectively).
Among the 1152 participants that developed at least one CD, the
mean age of onset of all newly developed CD was 59613 years
old. The mean age of occurrence of each newly developed
individual CD was determined (Figure 1, panel A). When
compared to this mean age of onset of all newly developed CDs,
the mean age of onset was lower for hypercholesterolemia (2461
years, p,0.0001), other mental disorders (2461 years, p,0.0001)
and asthma (2361 years, p,0.005). Conversely, COPD (+1061
years, p,0.0001), CVD (+1062 years, p,0.0001) and hyperten-
sion (+361 years, p,0.0001) were developed at an older age.
Comparison of baseline health status between chronic
diseases developed during the follow-up
Among those who developed at least one new CD during the
7.8 years of follow-up (n = 1152), 1793 CDs were developed and
619 occurred in healthy individuals and 1174 in those who had at
least one CD. The proportion of the total count of each CD
developed in those who were healthy at baseline and those that
had at least one CD is illustrated in Figure 1 (panel B).
Hypercholesterolemia represented 23% of the sum of all CDs
developed. Since an individual could develop more than one CD,
the proportion of the cohort that acquired the disease during the
follow-up was 39%. Among those that acquired hypercholester-
olima, 62% were healthy individuals at baseline while only 24%
had a CD at baseline (p,0.0001). There was no significant
difference in the proportion of cases that developed asthma (19%
vs. 22%) and other mental illness (13% vs. 16%) between
individuals without and with a CD at baseline in the crude model
but this difference reached significance in both adjusted models
(p,0.01 and p,0.05 respectively). The odds ratio of those with a
CD at baseline over those without was 4.04 (1.92–8.51), 2.37
(1.42–3.94) and 3.01 (2.09–4.36) for CVD, diabetes and COPD
new cases compared to the total number of CDs developed. Also,
among those who developed at least one CD during the follow-up,
8%, 11% and 25% of the individuals with a CD at baseline
acquired CVD, diabetes and COPD respectively while the
proportions were only 2%, 5% and 10% for those without.
Identification of baseline chronic diseases associated
with an increased the risk to develop chronic disease
during follow-up
Sixty percent of the population with at least one CD at baseline
developed at least another one during the 7.8 year of follow-up
(Figure 2). The proportion that developed CDs was significantly
lower in those with hypercholesterolemia (52%, p,0.0001) or
hypertension (53%, p,0.0001) at baseline. The proportion that
developed another CD was significantly higher in those with
asthma (65%, p,0.05) or mood and anxiety disorders (70%, p,
0.0001) at baseline. As a consequence, the prevalence of asthma
and mood and anxiety disorders at baseline were higher in those
that developed a CD ((OR: 1.37 (95%CI: 1.02–1.86) and 1.76
(1.25–2.49) respectively) than in those that did not.
Chronic diseases more likely to be developed by those
with asthma or depression at baseline
Since the presence of both asthma and mood and anxiety
disorders at baseline was associated with an increased risk of
developing another CD, the profile of CDs that those groups
developed were explored comparing them with those who had
another CD at baseline and that developed another CD (Table 3).
Individuals with asthma at baseline had a higher risk of developing
COPD (OR: 1.80; 95CI: 1.22–2.67) and hypercholesterolemia
(2.19; 1.48–3.25). Those having mood and anxiety disorders at
baseline were more likely to develop asthma (1.62; 1.05–2.49),




Age (mean ± SD, years old) 50±14
Related adults living together 125 (7)
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Relationship between mean age of occurrence and order
of appearance of chronic diseases developed during the
follow-up
Relationship between mean age of occurrence of a CD and the
order of appearance of a CD, expressed as the ratio of a CD to be
developed as a subsequent over a first CD, is illustrated in Panel A
of Figure 3. Briefly, hypercholesterolemia significantly occurs in
younger persons and as a first CD while COPD and CVD occurs
in older age groups after the occurrence of other CDs. While other
mental disorders and asthma occurs at a younger age, they are as
likely to occur as a first or as a subsequent CD. Diabetes is more
likely to occur after the occurrence of another CD despite
occurring closely to the mean age of occurrence of the eight CDs.
The relationship between the mean age of occurrence and the
proportion of participants with a specific CD at baseline to
developing a CD during the follow-up is illustrated in Panel B of
Figure 3. While occurring at a younger age, the proportion that
developed other CDs is significantly higher among those with
mood and anxiety disorder and those with asthma and lower for
those with hypercholesterolemia at baseline.
Discussion
This study contributes to the understanding of the evolution of
multimorbidity using longitudinal data. Briefly, the main findings
are: 1) Multimorbidity prevalence doubled over the 7.8 years of
follow-up, 2) Individual CDs have different mean age of onset and
order of appearance which are not always related and 3) some
CDs are associated with an increased risk of developing other
CDs(Figure 3, panel C).
Multimorbidity and its evolution during the study
Multimorbidity is a condition affecting an important proportion
of the population [2,3,4]. While multimorbidity has been shown to
increase with age [3,8], its longitudinal evolution is less investi-
gated [15]. The present study reports a multimorbidity prevalence
of 32% (with a mean age of 50 years old) that doubled over a mean
7.8 years of follow-up to reach 64%. This important increase in
multimorbidity prevalence is in line with a recent systematic
review [3], that reported that multimorbidity prevalence increases
with aging, with the highest rise between age 40 and 70.
Therefore, the present study, using a longitudinal design, confirms
the steep and important increased in the prevalence of multi-
morbidity with aging reported in cross sectional studies. Also, the
proportion of those with at least one CD was found to be similar to
those observed in general practitioner populations but higher than
those estimated in the general population [5].
Mean age of onset of chronic diseases developed during
follow-up
This study also presents differences in the mean age of onset for
eight CDs in the same population. Briefly, the mean age of onset of
asthma, hypercholesterolemia and other mental disorders is
younger while COPD, CVD and hypertension is older. While
mental disorders are known to occur at a young age [27], it is
surprising that mood and anxiety disorders are not frequent in the
younger age group, particularly considering that their respective
mean age of onset has been previously estimated to be 11 years for
anxiety and 30 years for mood disorders [27]. The reported mean
age of onset of diabetes, asthma and COPD are in line with
previous publications [28,29]. The present observations result
from incident cases from individuals over 18 years old and do not
take into account the age of onset of CDs already present at
Table 2. Proportion of the 1854 participants by number of CD and by individual CD status at baseline and follow-up and the
number and type of CD developed during the 7.8 years of follow-up.
CD count (n(% of column))
Baseline Follow-up New CD developed
CD count 2087 3880 1793
Number of CD
0 555 (30) 164(9)
1 714 (38) 496(27)
2 428 (23) 578 (31)
3 120 (7) 338 (18)
4+ 37(2) 278 (15)
Multimorbidity (2+) 585 (32) 1194 (64)
Individual CD
Asthma 219 (12) 463 (25) 244 (13)
COPD 67 (4) 293 (16) 226 (12)
Mood and anxiety disorders 176 (10) 385 (21) 209 (11)
Other mental disorders 120 (6) 290 (16) 170 (9)
Hypercholesterolemia 756 (41) 1178 (64) 422 (23)
Diabetes 127 (7) 228 (12) 101 (5)
CVD 96 (5) 163 (9) 67 (4)
Hypertension 526 (28) 880 (48) 354 (19)
COPD: Chronic obstructive pulmonary disease and CVD: Cardiovascular disease and stroke.
doi:10.1371/journal.pone.0096291.t002
Evolution of Multimorbidity
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baseline. Despite these limits, the mean age of onset is important in
understanding the evolution of multimorbidity and can be used to
compare factors associated with CD occurrence. To the best of our
knowledge, the comparison of age of onset for multiple CDs with
different aetiology has never been undertaken.
Integration of order of appearance and mean age of
occurrence for different chronic diseases
Hypercholesterolemia is more likely to occur at a younger age
and as a first CD. This is concordant with a previous study
showing that this CD was not associated with multimorbidity in
populations under 60 years old [4] and the role of the
hypercholesterolemia in diabetes and CVD development [30].
COPD and CVD had an older mean age of occurrence and were
more than twice as likely to develop after other CDs. Conversely,
hypertension, which also had an older mean age of occurrence, is
not more likely to occur as a subsequent CD than as a first.
Asthma and other mental illness, which occurs at a younger age,
were more likely to develop in those with a previous CD in both
models adjusted for age and sex. Briefly, hypercholesterolemia,
mood and anxiety disorders, COPD and CVD have a corre-
sponding mean age of occurrence and order of appearance but not
the other CDs.
Hypertension and hypercholesterolemia decrease the
risk of developing chronic diseases
Another finding of the present study is that the presence of
hypertension and hypercholesterolemia at baseline was signifi-
cantly associated with a lower risk of developing CDs. This could
be explained, at least partly, by the fact that statins and blood
pressure lowering drugs are known to delay the development of
some CDs such as CVD and diabetes [30]. While hypertension
and hypercholesterolemia were associated with a decreased risk of
developing other CDs, their high prevalence still makes them the
most common CD developed in individuals with existing CDs.
Mood and anxiety disorders increase the risk of
developing diabetes, asthma and other mental disorders
The presence of mood and anxiety disorders or asthma at
baseline was associated with an increased risk of developing other
CDs. Over a third of the individuals with a mood and anxiety
disorder develop another mental health problem over 7.8 years. It
is well known that mood and anxiety disorders could trigger
Figure 1. Comparison of chronic diseases developed during follow-by mean age of occurrence (Panel A), pre-existing CD status
(Panel B, table) and percent occurring as a first CD (Panel B, Figure). The Y axis of Panel A correspond to the estimated mean age (59) at
which CD were developed during follow-up. Error bar from panel A are confidence interval (95%). The Light and dark gray bars correspond to CD
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numerous other mental conditions [31,32]. Mood and anxiety
disorders are also associated with multiple physical conditions such
as diabetes, CVD, cancer and asthma [33,34,35,36,37]. In the
present cohort, 18% of the individuals with mood and anxiety
disorders developed diabetes over the 7.8 years of follow-up. This
increase is twice the one observed in other individuals who
developed at least another CD. Mood and anxiety disorders had
previously been associated with diabetes [34,35] and its develop-
ment [38]. Among the mechanisms proposed to explain this
association, the use of antidepressants, particularly tricyclics
antidepressants and selective serotonin reuptake inhibitors, in
individuals with mood and anxiety disorders has been associated
with an increased risk of developing abdominal obesity and
diabetes [38,39,40]. While some work has been done to determine
the impact of mood and anxiety disorders and its treatment on
comorbidities [41,42], not much has been undertaken to
determine their actual impact on other CD development. In light
of the present results showing an increased risk in individuals with
mood and anxiety disorders to develop diabetes, other mental
disorders and asthma, as well as its consequences on other CD
management and related complications [43,44], this study
supports the development of new approaches to address this
problem [41].
Asthma increases the risk of developing COPD and
hypercholesterolemia
In the present study, those with asthma at baseline were more
likely to develop COPD and hypercholesterolemia. While asthma
has a younger age of onset, it is also associated with higher
comorbidity rates [45]. In the present study, over 30% of those
that developed more than two CDs developed both hypercholes-
terolemia and asthma which suggest an association between those
two CDs (data not shown). In support of this hypothesis, asthma
has been related to a disorder in cholesterol metabolism [46,47].
However, much work needs to be done to better understand and
support this hypothesis. During the 7.8 years of follow-up, over
35% of the individuals with asthma developed COPD. This is in
line with a recently reported overlapping in both asthma and
COPD that could be associated with more frequent and severe
respiratory exacerbations despite a younger age and a reduced
lifetime smoking history. In the present study, the younger age
observed in this population supports this observation [48,49,50].
Limits
While data have been adjusted for risk factors such as age, sex,
education, marital status, working status, annual income and BMI,
some potential residual confounders, such as nutrition and
sedentary lifestyle, could still have an impact on multimorbidity
evolution [16]. The number of CDs investigated in the present
study (8) is also relatively small when compared to some
multimorbidity studies [3]. However, the diagnosis of most of
those CDs is based on biomedical measurement which is more
precise than most other data sources since it ensures consistency of
measurement despite potential change in CD definition, identifi-
cation and screening procedure. It also permits taking into account
undiagnosed conditions which has been previously shown to be
high for some CDs [51]. In the present study, those having a CD
were considered as having it for every phase afterward which
Figure 2. Proportion of individuals with a specific CD at baseline that developed at least one CD during the follow-up. The X-axis
correspond to the proportion (60%) of those that developed at least one CD during follow-up among those that had at least one CD at baseline.
*significantly different from the mean proportion of individual that developed CD. Error bar are confidence interval (95%).
doi:10.1371/journal.pone.0096291.g002
Evolution of Multimorbidity
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could have the potential to include milder forms of CD such as
milder hypertension which could be considered as solved with
appropriate lifestyle modifications. Also, individuals that died
during the follow-up are not included and this may bring an
immortal bias. However, this study is focusing on the evolution of
multimorbidity and not on the impact of CDs on mortality. The
quality of the diagnosis, the 7.8 years longitudinal follow-up and
the use of adapted control group are among the strengths of the
study.
Figure 3. Relationship of the CD mean age of occurrence with its order of appearance (Panel A) and the risk to develop CD during
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Conclusions
In summary, this study presents some of the first observations on
the evolution of multimorbidity. This approach shows the
importance of the increase in multimorbidity prevalence, that
CDs occur at different ages, in different order of appearance and
that their occurrence could have an impact on the development of
other CDs.
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